hematologic toxicity - Globe Thesis

Keyword [hematologic toxicity] Result: 1 - 13 \| Page: 1 of 1
1.	Kidney And Blood Side To Reduce The Clinical Studies Of Chemotherapy Hematologic Toxicity
2.	The Suppression Mechanisms Of Offspring Hematopoietic Function Exposed To Nucleoside Reverse Transcriptase Inhibitors During Pregnacy: The Disorder Of Hematopoietic Stem Cell
3.	Limitation Of Bone Marrow Dose In Pelvic Cancer Treated With Radiotherapy Alone Or Concurrent Radiochemotherapy Reduces Acute Hematologic Toxicity
4.	Factors Predicting Acute Hematologic Toxicity In Cervical Cancer Treated With Postoperative Intensity-Modulated Radiotherapy And Concurrent Nedaplatin
5.	Analysis Of Hematologic Toxicity And Bone Marrow Dosimetry In Cervical Cancer Patients Treated With Concurrent Chemotherapy And Extended Field Intensity Modulated Radiotherapy
6.	Relationship Of Dosimetric Parameters Of Irradiated Bone Marrow And Hematologic Toxicities In Locally Advanced Adenocarcinoma Of The Esophagogastric Junction Patients Treated With Preoperative Chemoradiotherapy
7.	Assosiation Between Bone Marrow Dose-volumetric Parameters And Acute Hematologic Toxicity In Anal Cancer Patients With Concurrent Chemoradiotherapy
8.	Clinical Intervention Of ‘Xuanji Acupuncture’ On The Treatment Of Hematologic Toxicity After Platinum-based Chemotherapy In Non-small Cell Lung Cancer
9.	The Curative Effect Of Chronic Myeloid Leukemia With Marrow Fibrosis Clinical Observation
10.	PBMS-IMRT Reduces The Incidence Of The Hematologic Toxicity Of Patients With Cervical Cancer Receiving Concurrent Chemoradiotherapy:A Single-center Prospective Randomized Controlled Trail
11.	The Effect Of Hematologic Toxicity At First Complete Remission And Its Recovery On The Prognosis Of Pediatric Acute Lymphoblastic Leukemia
12.	Association Between Sternal Dosimetric,Clinical Parameter And Hematological Toxicity Of Adjuvant Radiotherapy After Modified Radical Mastectomy For Breast Cancer
13.	Hematologic Toxicity And Kinetics Of Immune Function And Relevant Factors Analysis After Chimeric Antigen Receptor T Cells Therapy In Relapsed/Refractory Acute B Lymphoblastic Leukemia
<<First <Prev Next> Last>> Jump to